Effect of omeprazole on the metabolism of cilostazol

Clinical Pharmacokinetics

Volumn 37, Issue SUPPL. 2, 1999, Pages 53-59

  Suri, Ajit ^a   Bramer, Steven L ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDRO 6 [4 [1 (4 HYDROXYCYCLOHEXYL) 1H TETRAZOL 5 YL]BUTOXY] 2(1H) QUINOLINONE; CILOSTAZOL; DEHYDROCILOSTAZOL; DRUG METABOLITE; OMEPRAZOLE; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; EAR DISEASE; FEMALE; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RASH; VERTIGO;

EID: 0033496008     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937002-00006     Document Type: Article

References (20)

1. Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35 (7A): 1144-9
2. Kobriyama T, Tanaka E, Katayama S, et al. Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase - assessment of its effect on coagulation and fibrinolytic parameters. Rinsho Shinkeigaku 1994; 34 (8): 771-6
3. Uchikawa T, Murakami T, Furukawa H. Effects of the antiplatelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung 1992; 42 (3): 322-4
4. Okuda Y, Mizutani M, Ikegami T, et al. Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic nephropathy. Arzneimittelforschung 1992; 42 (4): 540-2
5. Tsuchikane E, Katoh O, Sumitsuji S, et al. Impact of cilostazol on intimal proliferation following directional coronary atherectomy: a prospective randomized trial. J Am Coll Cardiol 1997; 29 (2 Suppl. A): 397A
6. Suehiro A, Sugimoto Y, Masuda H, et al. A study of the effects of cilostazol on platelet function and serum lipids in patients with diabetes mellitus. Curr Ther Res 1993; 54 (5): 553-61
7. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998; 18 (12): 1942-7
8. Abbas R, Chow CP, Browder NJ, et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol. In press
9. Suri A, Forbes WP, Bramer SL. Effect of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37 Suppl. 2: 61-8
10. Anderson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21 (3): 195-212
11. Shimizu T, Osumi T, Niimi K, et al. Physico-chemical properties and stability of cilostazol. Arzneimittelforschung 1985; 35 (7A): 1117-23
12. Fu CJ, Tata PNV, Bramer SL. The quantitative determination of cilostazol and its metabolites simultaneously in human plasma by high performance liquid chromatography. J Chromatogr B Biomed Sci App 1999; 728 (2): 251-62
13. Akiyama H, Kudo S, Shimizu T. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 1985; 35 (7A): 1133-40
14. Akiyama H, Kudo S, Odomi M, et al. High-performance liquid chromatographic procedure for the determination of a new antithrombotic and vasodilating agent, cilostazol, in human plasma. J Chromatogr 1985; 338: 456-9
15. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics - principles of therapeutic drug monitoring. Spokane, WA: Applied Therapeutics, 1986
16. Suri A, Forbes WP, Bramer SL. Pharmacokinetics of multiple-dose oral cilostazol in middle-aged and elderly men and women. J Clin Pharmcol 1998; 38: 144-50
17. Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable Cyp2c19. Hepatology 1996; 23: 1491-7
18. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8: S21-5
19. Soucek P, Gut I. Cytochrome P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 1992; 22(1): 83-103
20. Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet 1999; 37 Suppl. 2: 13-23